Press Releases June 2, 2026 04:15 PM

Crescent Biopharma to Present at June Investor Conferences

Crescent Biopharma to Present at Major June Investor Conferences

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
CBIO

Crescent Biopharma, a clinical-stage biotechnology company focused on cancer therapies, announced that its management will present at the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026. The presentations will be webcast live and replayed on the company's investor website.

Crescent Biopharma to Present at June Investor Conferences
CBIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Crescent Biopharma focuses on oncology, developing a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs).
  • Management will present at two prominent healthcare investor conferences in June 2026, signaling active investor engagement.
  • The company aims to rapidly advance transformative therapies for a range of solid tumors using multiple modalities and combination regimens.

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

  • 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
  • Goldman Sachs 47th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami

A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
[email protected]
781-671-5019


Risks

  • Clinical-stage pipeline implies significant development and regulatory risks before commercial approval.
  • The biotechnology sector is highly competitive with uncertainties in trial outcomes and market acceptance.
  • Market reaction might be limited as the announcement is about investor presentations with no new data or milestones disclosed.

More from Press Releases

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy Sep 3, 2026 LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Sep 3, 2026 Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes Sep 2, 2026 Diversified Announces Accretive Acquisition of Birch Sep 2, 2026 Brady Corporation increases its dividend to shareholders for the 41st consecutive year Sep 2, 2026